(-0.12%) 5 140.75 points
(0.00%) 38 558 points
(-0.10%) 17 887 points
(0.29%) $82.87
(2.32%) $2.08
(-1.26%) $2 328.00
(-2.44%) $26.99
(-1.26%) $949.40
(-0.04%) $0.932
(0.29%) $11.01
(0.16%) $0.797
(-0.16%) $93.15
Live Chart Being Loaded With Signals
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. engages in the manufacture and sale of pharmaceutical products in Hong Kong, the United States, Europe, Mainland China, and internationally...
Stats | |
---|---|
Šios dienos apimtis | 7.05M |
Vidutinė apimtis | 501 174 |
Rinkos kapitalizacija | 13.52B |
EPS | HKD0.0135 ( 2023-09-30 ) |
Last Dividend | HKD0.112 ( 2023-05-24 ) |
Next Dividend | HKD0 ( N/A ) |
P/E | -5.79 |
ATR14 | HKD0.00800 (0.24%) |
Tūris Koreliacija
Shenzhen Hepalink Koreliacija
10 Labiausiai teigiamai susiję koreliacijos |
---|
10 Labiausiai neigiamai susiję koreliacijos |
---|
Ar žinojote?
Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).
Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.
Shenzhen Hepalink Koreliacija - Valiuta/Žaliavos
Shenzhen Hepalink Finansinės ataskaitos
Annual | 2023 |
Pajamos: | HKD5.45B |
Bruto pelnas: | HKD1.80B (33.06 %) |
EPS: | HKD-0.530 |
FY | 2023 |
Pajamos: | HKD5.45B |
Bruto pelnas: | HKD1.80B (33.06 %) |
EPS: | HKD-0.530 |
FY | 2022 |
Pajamos: | HKD7.16B |
Bruto pelnas: | HKD2.33B (32.61 %) |
EPS: | HKD0.500 |
FY | 2021 |
Pajamos: | HKD6.37B |
Bruto pelnas: | HKD2.03B (31.94 %) |
EPS: | HKD0.180 |
Financial Reports:
No articles found.
Shenzhen Hepalink Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
HKD0 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
HKD0.112 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
Very Unsafe
High risk of being cut
Unsafe
Heightened risk of being cut
Borderline
Moderate risk of being cut
Safe
Unlikely to be cut
Very Safe
Very unlikely to be cut
First Dividend | HKD0.180 | 2021-05-28 |
Last Dividend | HKD0.112 | 2023-05-24 |
Next Dividend | HKD0 | N/A |
Payout Date | 0000-00-00 | |
Next Payout Date | N/A | |
# dividends | 3 | -- |
Total Paid Out | HKD0.333 | -- |
Avg. Dividend % Per Year | 0.00% | -- |
Score | 1.36 | -- |
Div. Sustainability Score | 3.30 | |
Div.Growth Potential Score | 2.21 | |
Div. Directional Score | 2.75 | -- |
Year | Amount | Yield |
---|
The company's low Dividend Sustainability Score (DSS) highlights potential challenges in upholding its current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. In conclusion, a more vigilant stance is recommended given the company's tentative dividend landscape.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
3993.HK | Ex Dividend Junior | 2023-06-29 | Annually | 0 | 0.00% | |
1800.HK | Ex Dividend Junior | 2023-06-20 | Annually | 0 | 0.00% | |
0836.HK | Ex Dividend Knight | 2023-09-05 | Semi-Annually | 0 | 0.00% | |
0002.HK | Ex Dividend Knight | 2023-09-04 | Quarterly | 0 | 0.00% | |
2382.HK | Ex Dividend Junior | 2023-05-30 | Annually | 0 | 0.00% | |
1373.HK | Ex Dividend Knight | 2023-10-04 | Semi-Annually | 0 | 0.00% | |
0435.HK | Ex Dividend Knight | 2023-09-21 | Semi-Annually | 0 | 0.00% | |
6812.HK | Ex Dividend Junior | 2023-08-04 | Sporadic | 0 | 0.00% | |
1919.HK | Ex Dividend Knight | 2023-05-30 | Sporadic | 0 | 0.00% | |
0952.HK | Ex Dividend Junior | 2023-09-14 | Sporadic | 0 | 0.00% |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | -0.144 | 1.500 | -2.88 | -4.32 | [0 - 0.5] |
returnOnAssetsTTM | -0.0408 | 1.200 | -1.360 | -1.631 | [0 - 0.3] |
returnOnEquityTTM | -0.0638 | 1.500 | -1.820 | -2.73 | [0.1 - 1] |
payoutRatioTTM | -0.544 | -1.000 | -5.44 | 5.44 | [0 - 1] |
currentRatioTTM | 2.13 | 0.800 | 4.37 | 3.49 | [1 - 3] |
quickRatioTTM | 0.756 | 0.800 | -0.256 | -0.205 | [0.8 - 2.5] |
cashRatioTTM | 0.371 | 1.500 | 9.05 | 10.00 | [0.2 - 2] |
debtRatioTTM | 0.290 | -1.500 | 5.17 | -7.76 | [0 - 0.6] |
interestCoverageTTM | -3.86 | 1.000 | -2.54 | -2.54 | [3 - 30] |
operatingCashFlowPerShareTTM | 0.462 | 2.00 | 9.85 | 10.00 | [0 - 30] |
freeCashFlowPerShareTTM | 0.159 | 2.00 | 9.92 | 10.00 | [0 - 20] |
debtEquityRatioTTM | 0.467 | -1.500 | 8.13 | -10.00 | [0 - 2.5] |
grossProfitMarginTTM | 0.331 | 1.000 | 7.82 | 7.82 | [0.2 - 0.8] |
operatingProfitMarginTTM | -0.158 | 1.000 | -5.16 | -5.16 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | 0.122 | 1.000 | -0.433 | -0.433 | [0.2 - 2] |
assetTurnoverTTM | 0.284 | 0.800 | -1.443 | -1.154 | [0.5 - 2] |
Total Score | 3.30 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | -6.02 | 1.000 | -0.709 | 0 | [1 - 100] |
returnOnEquityTTM | -0.0638 | 2.50 | -1.170 | -2.73 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | 0.159 | 2.00 | 9.95 | 10.00 | [0 - 30] |
dividendYielPercentageTTM | 3.49 | 1.500 | 10.00 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | 0.462 | 2.00 | 9.85 | 10.00 | [0 - 30] |
payoutRatioTTM | -0.544 | 1.500 | -5.44 | 5.44 | [0 - 1] |
pegRatioTTM | -0.0488 | 1.500 | -3.66 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | 0.125 | 1.000 | 9.38 | 0 | [0.1 - 0.5] |
Total Score | 2.21 |
Shenzhen Hepalink
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. engages in the manufacture and sale of pharmaceutical products in Hong Kong, the United States, Europe, Mainland China, and internationally. The company operates through four segments: Finished dose pharmaceutical products, Active Pharmaceutical Ingredients (API), Contract Development and Manufacturing Organization, and Others. Its pharmaceutical products consist of finished dose pharmaceutical products, which primarily include enoxaparin sodium injection; API products, including heparin sodium API and enoxaparin sodium API; and other products, such as pancreatin API. The company is also involved in the provision of research and development, manufacturing, quality management, and program management services; and development and manufacture of recombinant pharmaceutical products, critical non-viral vectors, intermediates for gene therapy, and naturally derived pharmaceutical products. In addition, it engages in property management, investment management and consulting, biopharmaceutical technology development and consulting, and equity and venture investment activities; research, development, and production of biopharmaceuticals; production and sale of heparin sodium; provision of services on pharmaceutical related activities; and trading of medical and biopharmaceutical products. The company was formerly known as Shenzhen Hepalink Pharmaceutical Co.,Ltd. and changed its name to Shenzhen Hepalink Pharmaceutical Group Co., Ltd. in February 2017. Shenzhen Hepalink Pharmaceutical Group Co., Ltd. was founded in 1998 and is headquartered in Shenzhen, the People's Republic of China.
Apie Signalai gyvai
Šiame puslapyje pateikti tiesioginiai signalai padeda nustatyti, kada PIRKTI ar PARDUOTI NA. Signalai vėluoja 1 minutę; kaip ir su visais rinkos signalais, taip ir su šiais, visuomet yra klaidų tikimybė.
Tiesioginiai prekybos signalai nėra apibrėžti, todėl getagraph.com neprisiima atsakomybės už jokius veiksmus, kurių buvo imtasi žinant šiuos signalus, kaip aprašyta Naudojimo sąlygose. Signalai yra pagrįsti įvairiais techninės analizės rodikliais.